NCT03911557 2025-11-12Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid TumorsUniversity of KentuckyPhase 2 Completed14 enrolled
NCT03638141 2025-08-17CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and TremelimumabSidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 Completed21 enrolled 12 charts
NCT02821754 2023-03-28A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)National Institutes of Health Clinical Center (CC)Phase 2 Completed54 enrolled 14 charts